1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Jagsonpal Pharmaceuticals Ltd.

Jagsonpal Pharmaceuticals Ltd.

210.86
INR
-7.05
(-3.24%)
6.67EPS
35.14P/E
15.68BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
21.98
21.09
21.91
21.97
19.32
25.47
24.21
28.69
33.22
36.14
31.56
40.11
42.66
43.78
Basic EPS, GAAP
0.32
0.18
0.5
1.81
-1.76
1.1
1.2
2.6
2.88
4.08
3.4
8.26
6.4
6.77
Free Cash Flow per Basic Share
1.15
0.66
1.38
-0.89
-0.24
4.72
1.81
4.31
0.9
7.07
5.28
8.17
6.93
- -
Dividend per Share
0.2
0.04
0.04
0.04
0.04
0.1
0.2
0.4
1.6
- -
1.98
1.97
2.47
- -
Book Value per Share
15.05
14.09
15.02
16.78
14.97
15.95
16.95
19.07
20.27
24.26
28.35
36.14
41.24
- -
Tangible Book Value per Share
15.05
14.09
15.01
16.78
14.65
15.63
16.59
19.06
20.27
24.26
28.35
23.24
29.6
- -
Basic Weighted Avg Shares
65
65
65
65
65
65
65
65
65
65
66
67
67
67
Sales/Revenue/Turnover
1,439
1,382
1,435
1,439
1,265
1,668
1,586
1,879
2,176
2,367
2,087
2,687
2,872
2,938
Operating Margin (%)
5.5
4.43
6.49
2.86
-8.94
5.07
4.67
10
11.28
14.5
10.35
15.98
16.93
17.65
Depreciation Expense
28
27
31
20
11
10
11
11
15
12
17
81
94
92
Net Income, GAAP
21
12
33
119
-116
72
79
171
189
267
225
554
431
455
Effective Tax Rate (%)
16.22
29.95
20.15
17.59
- -
19.85
16.4
22.01
29.23
23.23
24.79
20.75
25.1
25.16
Profit Margin (%)
1.47
0.85
2.27
8.25
-9.13
4.33
4.96
9.08
8.67
11.29
10.76
20.6
15
15.48
Working Capital
377
406
436
807
660
694
617
810
821
1,370
1,777
1,353
1,148
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
52
76
76
66
- -
Total Equity
986
954
984
1,099
980
1,045
1,110
1,249
1,328
1,589
1,874
2,400
2,762
- -
Return on Invested Capital (%)
1.59
0.87
2.4
9.11
- -
5.92
5.08
11.18
12.61
15.72
9.04
22.37
13.09
- -
Return on Capital (%)
4.98
3.02
5.4
10.92
- -
7.06
7.26
13.96
14.4
18.1
12.76
25.16
16.38
- -
Return on Common Equity (%)
2.15
1.21
3.36
11.39
-11.11
7.13
7.3
14.46
14.64
18.32
12.97
25.91
16.69
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
16
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
66
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
67
66
Market Capitalization
12,863
12,323
15,675

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,431
- -
Cash, Cash Equivalents & STI
- -
1,061
- -
Accounts Receivable, Net
- -
172
- -
Inventories
- -
146
- -
Total Current Liabilities
- -
283
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
16
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.33%
17.41%
15.1%
Free Cash Flow
-159.38%
125.65%
-14.79%
Net Income, GAAP
19.12%
32.12%
-22.18%
Sales/Revenue/Turnover
8.2%
9.68%
6.89%
Total Cash Common Dividend
- -
- -
25.92%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
614
747
740
586
2,687
2026
756
745
729
642
2,872
2027
822
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.78
1.72
4.74
0.98
8.26
2026
1.6
1.88
1.67
1.25
6.4
2027
2
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.97
2026
- -
- -
- -
- -
2.47
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Manish Gupta
Full Time Employees
1,305
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
Nimai Tower Gurugram HA India 122015
IPO Date
Jul 1, 2002
Website
jagsonpal.com
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A (TWSE:1762)
Business
Jagsonpal Pharmaceuticals Limited manufactures, sells and trades pharmaceutical formulations and active pharmaceutical ingredients in India and internationally. The company offers products in gynaecology, orthopaedics, dermatology, paediatrics, antibiotics, allergy management, immunity and cell protection, OTC products; formulations include tablets, softgels, injections, capsules and syrups such as Maintane, Metabolin, Parvon, Rowezy and Queezy; it maintains 17 brands among the top five in their molecule categories, with top five brands contributing about 47% and top seven about 67% of revenues. Founded in 1978 and headquartered in New Delhi, India, Jagsonpal operates through a sales team of over 900 personnel with a pan-India presence and serves healthcare professionals and government institutions. In 2024, the company acquired the India and Bhutan businesses of Yash Pharma, integrating 33 established brands in dermatology and paediatrics to expand into a market segment valued at INR 20,000 crore and enhance therapeutic reach. It recently appointed a chief operating officer and chief financial officer, reported half-year revenue of INR 150.1 million and PAT of INR 234 million for FY26 with 10.2% and 39.2% year-over-year growth respectively, and sustains strong profit growth of 38.2% CAGR over five years while remaining nearly debt-free.